Danielle Jandial

1.3k total citations
20 papers, 893 citations indexed

About

Danielle Jandial is a scholar working on Oncology, Molecular Biology and Rheumatology. According to data from OpenAlex, Danielle Jandial has authored 20 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Rheumatology. Recurrent topics in Danielle Jandial's work include Bone health and treatments (7 papers), Bone Tumor Diagnosis and Treatments (5 papers) and Sarcoma Diagnosis and Treatment (4 papers). Danielle Jandial is often cited by papers focused on Bone health and treatments (7 papers), Bone Tumor Diagnosis and Treatments (5 papers) and Sarcoma Diagnosis and Treatment (4 papers). Danielle Jandial collaborates with scholars based in United States, United Kingdom and France. Danielle Jandial's co-authors include William M. Gilbert, Beate Danielsen, Nancy T. Field, Tian Dai, Lauren Krill, Xiaolin Zi, Yanbing Zhang, Christopher Blair, Sai‐Yang Zhang and Ying Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Danielle Jandial

19 papers receiving 870 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danielle Jandial United States 13 320 232 216 178 142 20 893
Jong‐Min Lee South Korea 21 410 1.3× 73 0.3× 107 0.5× 218 1.2× 10 0.1× 76 1.4k
Roman Crazzolara Austria 17 285 0.9× 36 0.2× 53 0.2× 385 2.2× 15 0.1× 58 1.1k
Ahmed Hamed Egypt 13 98 0.3× 45 0.2× 56 0.3× 160 0.9× 6 0.0× 41 598
Vinod H. Nargund United Kingdom 15 162 0.5× 143 0.6× 363 1.7× 182 1.0× 2 0.0× 36 1.0k
Naomi Yoshida Japan 18 80 0.3× 60 0.3× 51 0.2× 264 1.5× 7 0.0× 54 862
Shilpa Jain United States 12 120 0.4× 37 0.2× 154 0.7× 252 1.4× 15 0.1× 46 745
Takuji Kishimoto Japan 15 164 0.5× 13 0.1× 239 1.1× 189 1.1× 6 0.0× 64 802
Karen Maughan United Kingdom 10 215 0.7× 22 0.1× 61 0.3× 100 0.6× 6 0.0× 11 594
Pratibha Singh India 12 79 0.2× 51 0.2× 29 0.1× 159 0.9× 7 0.0× 118 803
Roya Dolatkhah Iran 15 303 0.9× 49 0.2× 125 0.6× 125 0.7× 3 0.0× 80 864

Countries citing papers authored by Danielle Jandial

Since Specialization
Citations

This map shows the geographic impact of Danielle Jandial's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Jandial with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Jandial more than expected).

Fields of papers citing papers by Danielle Jandial

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Jandial. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Jandial. The network helps show where Danielle Jandial may publish in the future.

Co-authorship network of co-authors of Danielle Jandial

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle Jandial. A scholar is included among the top collaborators of Danielle Jandial based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle Jandial. Danielle Jandial is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Jianhui, Arkene Levy, Zhen Cai, et al.. (2025). Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. Molecular Cancer Therapeutics. 24(8). 1171–1185. 1 indexed citations
2.
Kim, Daehwan, Olivier Harismendy, Catherine Lee, et al.. (2025). Abstract 372: Loss of RB1 sensitizes TP53-mutated cancer cells to WEE1 inhibition by azenosertib. Cancer Research. 85(8_Supplement_1). 372–372.
3.
Paz‐Ares, Luis, Enriqueta Felip, Myung‐Ju Ahn, et al.. (2023). Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE),compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).. Journal of Clinical Oncology. 41(16_suppl). TPS8611–TPS8611. 5 indexed citations
4.
Ramalingam, Suresh S., Myung‐Ju Ahn, Hiroaki Akamatsu, et al.. (2022). Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).. Journal of Clinical Oncology. 40(16_suppl). TPS8603–TPS8603. 5 indexed citations
5.
Palmerini, Emanuela, Leanne L. Seeger, Marco Gambarotti, et al.. (2021). Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. BMC Cancer. 21(1). 89–89. 27 indexed citations
6.
Coleman, Robert E., Ying Zhou, Danielle Jandial, Benoît Cadieux, & Arlene Chan. (2021). Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. Advances in Therapy. 38(8). 4569–4580. 12 indexed citations
7.
Bukata, Susan V., Jean‐Yves Blay, Piotr Rutkowski, et al.. (2020). Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum. Spine. 46(5). 277–284. 26 indexed citations
8.
Coleman, Robert E., Dianne M. Finkelstein, Carlos H. Barrios, et al.. (2019). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology. 21(1). 60–72. 158 indexed citations
9.
Chawla, Sant P., Jean‐Yves Blay, Piotr Rutkowski, et al.. (2019). Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. The Lancet Oncology. 20(12). 1719–1729. 155 indexed citations
10.
Liede, Alexander, Rohini K. Hernandez, En‐Tzu Tang, et al.. (2018). Epidemiology of benign giant cell tumor of bone in the Chinese population. Journal of bone oncology. 12. 96–100. 22 indexed citations
11.
Coleman, Robert E., Dianne M. Finkelstein, Carlos H. Barrios, et al.. (2018). Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.. Journal of Clinical Oncology. 36(15_suppl). 501–501. 41 indexed citations
12.
Schiødt, Morten, Saroj Vadhan‐Raj, Mark S. Chambers, et al.. (2017). A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Supportive Care in Cancer. 26(6). 1905–1915. 44 indexed citations
13.
Palmerini, Emanuela, Jean‐Yves Blay, Axel Le Cesne, et al.. (2017). Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study. Annals of Oncology. 28. v645–v646. 5 indexed citations
14.
Jandial, Danielle, William E. Brady, Stephen B. Howell, et al.. (2017). A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 145(2). 236–242. 17 indexed citations
15.
Jandial, Danielle, Lauren Krill, Lixia Chen, et al.. (2017). Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin. Molecules. 22(3). 462–462. 40 indexed citations
16.
Schiødt, Morten, Saroj Vadhan‐Raj, Mark S. Chambers, et al.. (2016). Multicenter case registry study on medication-related osteonecrosis of the jaw in advanced cancer patients.. Journal of Clinical Oncology. 34(15_suppl). e21663–e21663. 1 indexed citations
17.
Kwa, Maryann & Danielle Jandial. (2015). Modulation of intraperitoneal (IP) chemotherapy in ovarian cancer. Translational Cancer Research. 4(1). 60–69. 3 indexed citations
18.
Jandial, Danielle, Christopher Blair, Sai‐Yang Zhang, et al.. (2014). Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones. Current Cancer Drug Targets. 14(2). 181–200. 114 indexed citations
19.
Gilbert, William M., et al.. (2004). Birth outcomes in teenage pregnancies. The Journal of Maternal-Fetal & Neonatal Medicine. 16(5). 265–270. 116 indexed citations
20.
Gilbert, William M., et al.. (2004). Birth outcomes in teenage pregnancies. The Journal of Maternal-Fetal & Neonatal Medicine. 16(5). 265–270. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jong‐Min Lee Breakdown of academic impact, for papers by Roman Crazzolara Breakdown of academic impact, for papers by Ahmed Hamed Breakdown of academic impact, for papers by Vinod H. Nargund Breakdown of academic impact, for papers by Naomi Yoshida Breakdown of academic impact, for papers by Shilpa Jain Breakdown of academic impact, for papers by Takuji Kishimoto Breakdown of academic impact, for papers by Karen Maughan Breakdown of academic impact, for papers by Pratibha Singh Breakdown of academic impact, for papers by Roya Dolatkhah
Rankless by CCL
2026